RxDoctor Payments Data

Bradley Dowden, MD

Internal Medicine · Lafayette, LANPI 1164432415

Payments from drug & device makers

$877in general payments, 2019–2025

Across 55 payments — averaging $15.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$202
  • AstraZeneca$98
  • Novo Nordisk$91
  • Lilly USA, LLC$75
  • Pfizer$57
  • GSK$53
  • plus $300 from 14 others

What the payments were for

  • Food & beverage$877100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$877 in reported general payments places this provider in the 60th percentile of 1,528 internal medicine providers in Louisiana.

See all internal medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$214,713
Medicare patients
416
Services billed
2,841

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide67$68,359
EliquisApixaban58$44,913
JanuviaSitagliptin Phosphate44$43,306
JardianceEmpagliflozin41$40,117
MounjaroTirzepatide25$33,743
FarxigaDapagliflozin Propanediol27$22,828
OzempicSemaglutide21$19,794
XareltoRivaroxaban20$17,435
Breo ElliptaFluticasone/Vilanterol28$14,734
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$12,883
ArexvyRsvpref3 Antigen/As01e/Pf29$9,102
ShingrixVaricella-Zoster Ge/As01b/Pf36$8,043
TrintellixVortioxetine Hydrobromide17$7,882
Lantus SolostarInsulin Glargine,hum.Rec.Anlog41$7,574
Stiolto RespimatTiotropium Br/Olodaterol Hcl12$7,344

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$75$102,10292 claims
Boehringer IngelheimJardiance, Stiolto Respimat$37$47,46053 claims
PfizerEliquis$57$44,91358 claims
GSKBreo Ellipta, Trelegy Ellipta, Arexvy, Shingrix$53$44,761114 claims
AstraZenecaFarxiga$98$22,82827 claims
Novo NordiskOzempic$91$19,79421 claims
Johnson & JohnsonXarelto$15$17,43520 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$15$5,98712 claims
AbbVieSynthroid$202$3,52857 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,528 internal medicine providers in Louisiana.

Other internal medicine in Lafayette

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →